[1] |
Khan KH, Goody RB, Hameed H, et al. Metastatic melanoma: a regional review and future directions[J]. Tumori, 2012,98(5):575⁃580. doi: 10.1700/1190.13197.
|
[2] |
Erdmann F, Lortet⁃Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma 1953⁃2008⁃⁃are recent generations at higher or lower risk?[J]. Int J Cancer, 2013,132(2):385⁃400. doi: 10.1002/ijc.27616.
|
[3] |
Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma[J]. Curr Opin Oncol, 2015,27(2):141⁃150. doi: 10.1097/CCO.0000000000000159.
|
[4] |
Sheng Y, Hong JH, Doherty R, et al. A human ubiquitin conjugating enzyme (E2)⁃HECT E3 ligase structure⁃function screen[J]. Mol Cell Proteomics, 2012,11(8):329⁃341. doi: 10. 1074/mcp.O111.013706.
|
[5] |
Chang L, Zhang Z, Yang J, et al. Atomic structure of the APC/C and its mechanism of protein ubiquitination[J]. Nature, 2015,522(7557):450⁃454. doi: 10.1038/nature14471.
|
[6] |
Garnett MJ, Mansfeld J, Godwin C, et al. UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit[J]. Nat Cell Biol, 2009,11(11):1363⁃1369. doi: 10.1038/ncb1983.
|
[7] |
马阳阳, 王平, 胡文婷, 等. 泛素结合酶2S在恶性黑素瘤中的表达及其对黑素瘤细胞生物学行为的影响[J]. 中华皮肤科杂志, 2019,52(8):542⁃547. doi: 10.3760/cma.j.issn.0412⁃4030. 2019.08.006.
|
[8] |
Garbe C, Krasagakis K, Zouboulis CC, et al. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype[J]. J Invest Dermatol, 1990,95(6 Suppl):231S⁃237S. doi: 10.1111/1523⁃1747.ep12875837.
|
[9] |
Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade[J]. J Transl Med, 2008,6:62. doi: 10.1186/1479⁃5876⁃6⁃62.
|
[10] |
Wang W, Edington HD, Rao UN, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high⁃dose IFNalpha2b[J]. Clin Cancer Res, 2007,13(5):1523⁃1531. doi: 10.1158/1078⁃0432.CCR⁃06⁃1387.
|
[11] |
Zhang Y, Liu Z. STAT1 in cancer: friend or foe?[J]. Discov Med, 2017,24(130):19⁃29.
|
[12] |
van der Veen AG, Ploegh HL. Ubiquitin⁃like proteins[J]. Annu Rev Biochem, 2012,81:323⁃357. doi: 10.1146/annurev⁃biochem⁃093010⁃153308.
|
[13] |
Recht M, Borden EC, Knight E Jr. A human 15⁃kDa IFN⁃induced protein induces the secretion of IFN⁃gamma[J]. J Immunol, 1991,147(8):2617⁃2623.
|
[14] |
Han HG, Moon HW, Jeon YJ. ISG15 in cancer: beyond ubiquitin⁃like protein[J]. Cancer Lett, 2018,438:52⁃62. doi: 10.1016/j.canlet.2018.09.007.
|
[15] |
Kong E, Kim HD, Kim J. Deleting key autophagy elongation proteins induces acquirement of tumor⁃associated phenotypes via ISG15[J]. Cell Death Differ, 2020,27(8):2517⁃2530. doi: 10.1038/s41418⁃020⁃0519⁃y.
|
[16] |
Fan JB, Miyauchi S, Xu HZ, et al. Type I interferon regulates a coordinated gene network to enhance cytotoxic T cell⁃mediated tumor killing[J]. Cancer Discov, 2020,10(3):382⁃393. doi: 10.1158/2159⁃8290.CD⁃19⁃0608.
|
[17] |
Meuwissen ME, Schot R, Buta S, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo⁃TORCH syndrome[J]. J Exp Med, 2016,213(7):1163⁃1174. doi: 10.1084/jem.20151529.
|
[18] |
Perkins ND. Integrating cell⁃signalling pathways with NF⁃kappaB and IKK function[J]. Nat Rev Mol Cell Biol, 2007,8(1):49⁃62. doi: 10.1038/nrm2083.
|
[19] |
Lin CY, Gustafsson JÅ. Targeting liver X receptors in cancer therapeutics[J]. Nat Rev Cancer, 2015,15(4):216⁃224. doi: 10.1038/nrc3912.
|
[20] |
Fukuchi J, Kokontis JM, Hiipakka RA, et al. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells[J]. Cancer Res, 2004,64(21):7686⁃7689. doi: 10.1158/0008⁃5472.CAN⁃04⁃2332.
|
[21] |
Castrillo A, Joseph SB, Marathe C, et al. Liver X receptor⁃dependent repression of matrix metalloproteinase⁃9 expression in macrophages[J]. J Biol Chem, 2003,278(12):10443⁃10449. doi: 10.1074/jbc.M213071200.
|
[22] |
Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling[J]. Cytokine Growth Factor Rev, 2004,15(6):457⁃475. doi: 10.1016/j.cytogfr.2004.06.004.
|
[23] |
Oliver JL, Alexander MP, Norrod AG, et al. Differential expression and tumor necrosis factor⁃mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas[J]. Pigment Cell Melanoma Res, 2013,26(4):571⁃579. doi: 10. 1111/pcmr.12091.
|
[24] |
Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer[J]. Clin Cancer Res, 2011,17(8):2444⁃2450. doi: 10.1158/1078⁃0432.CCR⁃10⁃2884.
|
[25] |
Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer[J]. Clin Cancer Res, 2011,17(4):805⁃816. doi: 10.1158/1078⁃0432.CCR⁃10⁃0248.
|